GIP (glucose-dependent insulinotropic polypeptide) was long dismissed as a clinically uninteresting incretin hormone. In type 2 diabetes, GIP appears to have blunted its own receptor response — a phenomenon called GIP resistance — leading researchers in the 2000s to largely focus development on the more potent GLP-1 receptor. What changed the calculus was a series of mechanistic studies in the 2010s showing that combining GIP receptor agonism with GLP-1 receptor agonism in animal models produced substantially greater weight loss than either alone. The GIP receptor, it turned out, was still functionally active in adipose tissue and in the brain's hypothalamus even when blunted at the pancreatic β-cell — and stimulating both receptors simultaneously created synergistic weight-loss effects that exceeded the sum of their parts.
Tirzepatide (brand names: Mounjaro for T2DM, Zepbound for obesity) is a synthetic peptide designed to be a "twincretin" — a single molecule that activates both GIP and GLP-1 receptors. It is not a mixture of two drugs; it is one engineered peptide with dual agonist activity at both receptors simultaneously. Semaglutide (brand names: Ozempic 0.5/1/2mg for T2DM, Wegovy 2.4mg for obesity, Rybelsus oral for T2DM) is a selective GLP-1 receptor agonist — highly potent at GLP-1R with minimal GIP receptor activity. Understanding the clinical difference between these two drugs requires understanding what GIP adds to GLP-1 and why that difference is measurable in the weight loss data.
SURMOUNT-1 vs STEP 1
the definitive weight loss comparison between drug classes: SURMOUNT-1 (Jastreboff AM et al., 2022, New England Journal of Medicine, PMID 35658024): DESIGN: 72-week, double-blind, placebo-controlled RCT; POPULATION: N=2,539 adults with BMI ≥30 (or ≥27 + one comorbidity); NO T2DM (excluded); INTERVENTION: tirzepatide 5mg, 10mg, or 15mg weekly SC injection vs placebo; DOSE ESCALATION: gradual increase over 20 weeks; PRIMARY ENDPOINTS: (1) % change in body weight from baseline; (2) ≥5% weight loss response; KEY RESULTS at 72 weeks: tirzepatide 5mg: −15.0% body weight; tirzepatide 10mg: −19.5%; tirzepatide 15mg: −20.9%; placebo: −3.1%; RESPONDER ANALYSIS (≥5% weight loss): 89% of 5mg, 96% of 10mg, 96% of 15mg patients vs 28% placebo; ≥10% weight loss: 67%, 85%, 87% vs 10%; ≥15% weight loss: 42%, 67%, 71% vs 5%; ≥20% weight loss: 24%, 47%, 57% vs 3%; 57% of 15mg patients achieved ≥20% weight loss — a threshold previously achievable only with bariatric surgery; STEP 1 (Wilding JH et al., 2021, New England Journal of Medicine, PMID 33567185): DESIGN: 68-week, double-blind, placebo-controlled RCT; POPULATION: N=1,961 adults with BMI ≥30 (or ≥27 + comorbidity); NO T2DM (excluded); INTERVENTION: semaglutide 2.4mg weekly SC vs placebo; KEY RESULTS at 68 weeks: semaglutide 2.4mg: −14.9% body weight; placebo: −2.4%; ≥5% weight loss: 86.4% vs 31.5%; ≥10% weight loss: 69.1% vs 12%; ≥15% weight loss: 50.5% vs 4.9%; ≥20% weight loss: 32.0% vs 1.7%; DIRECT COMPARISON: tirzepatide 15mg (−20.9%) vs semaglutide 2.4mg (−14.9%) = approximately 6 percentage points greater weight loss with the dual agonist; the SURMOUNT-1 and STEP 1 populations are clinically similar (non-diabetic obesity, similar inclusion criteria) but the trials are different duration (72 vs 68 weeks) and differ slightly in protocol — caution when comparing across trials; SURPASS-2 provides the only head-to-head data (but in T2DM)
SURPASS-2 Head-to-Head
the only direct RCT comparison (in T2DM): SURPASS-2 (Frías JP et al., 2021, New England Journal of Medicine, PMID 34170647): DESIGN: 40-week, open-label RCT; POPULATION: N=1,879 adults with T2DM, inadequately controlled on metformin; note: open-label design (patients/providers knew which drug they were taking); INTERVENTION: tirzepatide 5mg, 10mg, or 15mg weekly SC vs semaglutide 1mg weekly SC (the standard T2DM dose of semaglutide, NOT the higher obesity dose of 2.4mg); PRIMARY ENDPOINT: HbA1c change from baseline; KEY RESULTS at 40 weeks: HbA1c reduction — tirzepatide 5mg: −2.01%; tirzepatide 10mg: −2.24%; tirzepatide 15mg: −2.30%; semaglutide 1mg: −1.86%; all tirzepatide doses achieved HbA1c ≤6.5% (ADA target) more often than semaglutide; BODY WEIGHT CHANGE: tirzepatide 5mg: −7.6kg; tirzepatide 10mg: −10.9kg; tirzepatide 15mg: −13.1kg; semaglutide 1mg: −6.2kg; the 13.1kg vs 6.2kg difference is clinically striking — tirzepatide 15mg produced more than double the weight loss of standard semaglutide 1mg in T2DM; CARDIOVASCULAR MARKERS: both drugs improved systolic BP, LDL, triglycerides; tirzepatide showed greater reductions; LIMITATIONS OF SURPASS-2: open-label design is a risk for placebo effects on behavioral outcomes; semaglutide was at 1mg (T2DM dose), not 2.4mg (obesity dose — not yet approved for T2DM); the most direct comparison would be tirzepatide 15mg vs semaglutide 2.4mg in the same population in the same trial — this has not yet been done in a large preregistered RCT (as of mid-2026); SURPASS-CVOT (AMPLITUDE-O equivalent for tirzepatide): tirzepatide's cardiovascular outcomes trial is ongoing/results pending as of 2026; until SURPASS-CVOT reports, tirzepatide lacks the Class I cardiovascular endpoint data that semaglutide acquired via the SELECT trial (2023)
GIP Receptor Biology
why adding GIP to GLP-1 produces additive weight loss: GIP (glucose-dependent insulinotropic polypeptide): 42 amino acid peptide; secreted by K cells of the small intestine in response to fat and glucose ingestion (vs GLP-1 secreted by L cells in the distal gut); the first incretin described (before GLP-1); key effects of GIP receptor activation: PANCREATIC: stimulates insulin secretion (glucose-dependent; like GLP-1); unlike GLP-1, also stimulates glucagon at low glucose → less hypoglycemia risk than GLP-1 alone; ADIPOSE TISSUE: GIP receptor is strongly expressed in adipocytes; in metabolic health, GIP promotes fat storage (lipogenesis); at the pharmacologically exaggerated doses achieved with tirzepatide, however, GIP receptor activation in adipose tissue combined with GLP-1R activation may paradoxically promote lipid mobilization from fat stores — the mechanism of additive weight loss over GLP-1 alone; the exact mechanism of GIP's weight contribution in tirzepatide is still under active investigation (GIP may be activating different pathways than GLP-1 in the hypothalamus, or the two receptors may heterodimerize); CNS: GIP receptors are present in the hypothalamus, hippocampus, and ventral tegmental area; hypothalamic GIP-R activation suppresses appetite via pathways distinct from GLP-1R; BONE: GIP receptor activation promotes osteoblast activity → bone formation; this may explain why tirzepatide appears bone-neutral or even bone-protective, unlike GLP-1 monotherapy where significant weight loss can reduce bone mineral density; normal caloric restriction and weight loss reduce bone density — GLP-1 alone is somewhat bone-neutral, but tirzepatide's GIP component may actively promote bone formation to offset the weight-loss-induced bone loss; NAUSEA PROFILE: tirzepatide's nausea incidence at 15mg in SURMOUNT-1: ~36% vs 9% placebo; semaglutide 2.4mg nausea in STEP 1: ~44% vs 16% placebo; some analyses suggest tirzepatide may be slightly better tolerated than semaglutide at comparable weight loss efficacy, but the comparison is complicated by different dose regimens and trial populations; GIP resistance in T2DM: GIP receptor signaling is impaired in pancreatic β-cells of T2DM patients — this is why early drug developers dismissed GIP agonism for diabetes; however, tirzepatide data suggests that supraphysiologic GIP agonism can overcome this resistance, and the extrapancreatic GIP effects (adipose, brain, bone) may be less affected by disease-state GIP resistance
SELECT Trial + Cardiovascular Gap
where semaglutide has evidence tirzepatide does not yet have: SELECT TRIAL (Lincoff AM et al., 2023, New England Journal of Medicine, PMID 37979063): DESIGN: 3-year, double-blind, placebo-controlled CVOT (cardiovascular outcomes trial); POPULATION: N=17,604 overweight/obese adults WITHOUT T2DM but WITH established cardiovascular disease (prior MI, stroke, or symptomatic peripheral arterial disease); INTERVENTION: semaglutide 2.4mg weekly SC vs placebo; PRIMARY ENDPOINT: MACE (major adverse cardiovascular events — cardiovascular death, non-fatal MI, non-fatal stroke); KEY RESULT: semaglutide 2.4mg: HR 0.80 (95% CI 0.72–0.90), p<0.001 → −20% relative reduction in MACE; absolute risk: 6.5% vs 8.0% (placebo); LANDMARK: SELECT is the first trial in history to demonstrate that a weight loss drug (not just a diabetes drug) reduces cardiovascular events in non-diabetic obese patients with CVD; it establishes semaglutide 2.4mg as a legitimate cardiovascular medication, not merely a weight management tool; TIRZEPATIDE CARDIOVASCULAR GAP: tirzepatide received FDA approval for T2DM (Mounjaro, May 2022) and obesity (Zepbound, November 2023) without a completed large-scale cardiovascular outcomes trial; SURPASS-CVOT is ongoing; for patients with established CVD and obesity, the current evidence-based choice is semaglutide 2.4mg — the SELECT trial provides Class I, Level A evidence for cardiovascular benefit; WHEN TIRZEPATIDE WINS: the weight loss data strongly favors tirzepatide for patients whose primary goal is maximum weight reduction — T2DM or obesity without established CVD where metabolic efficacy is the priority; patients who did not achieve adequate weight loss on semaglutide; the ongoing SURPASS-CVOT trial will determine whether tirzepatide also earns cardiovascular indications; LEADER TRIAL COMPARISON: LEADER (liraglutide, 2016) showed MACE benefit in T2DM; SUSTAIN-6 (semaglutide 0.5/1mg) in T2DM; SELECT extended the cardiovascular benefit to non-diabetic obesity — a clinically transformative finding for the GLP-1 class broadly
| Feature | Tirzepatide (Mounjaro/Zepbound) | Semaglutide (Ozempic/Wegovy) |
|---|
| Mechanism | Dual GIP+GLP-1 receptor agonist | Selective GLP-1 receptor agonist |
| Peak weight loss (obesity RCT) | −20.9% (15mg, SURMOUNT-1) | −14.9% (2.4mg, STEP 1) |
| HbA1c reduction (T2DM) | −2.30% (15mg, SURPASS-1) | −1.86% (1mg, SURPASS-2) |
| Cardiovascular outcomes trial | SURPASS-CVOT (pending) | SELECT 2023: −20% MACE ✓ |
| Dosing | 2.5→5→7.5→10→12.5→15mg weekly | 0.25→0.5→1→2.4mg weekly (Wegovy) |
| T2DM approval | May 2022 (Mounjaro) | 2017/2021 (Ozempic) |
| Obesity approval | November 2023 (Zepbound) | June 2021 (Wegovy) |
| Oral form available | No (injection only) | Yes (Rybelsus 3/7/14mg, T2DM only) |
| GI side effects (nausea) | ~36% nausea (15mg) | ~44% nausea (2.4mg) |
| Bone effect | May be bone-protective (GIP) | Neutral (slight benefit vs weight loss alone) |
Clinical Decision Framework — Which Drug When
Choose semaglutide 2.4mg (Wegovy) when: ESTABLISHED CARDIOVASCULAR DISEASE (prior MI, stroke, symptomatic PAD) + obesity WITHOUT T2DM → SELECT trial provides Class I evidence for MACE reduction; this is the only scenario where a specific CV benefit is proven; preferred by cardiologists until SURPASS-CVOT reports; ADEQUATE WEIGHT LOSS ACHIEVED PREVIOUSLY ON SEMAGLUTIDE: there is no clinical rationale to switch to tirzepatide if a patient is responding well on semaglutide with good tolerability; ORAL INCRETIN PREFERRED: Rybelsus (oral semaglutide) is available for T2DM; no oral tirzepatide is approved (as of mid-2026); INSURANCE COVERAGE IS BETTER FOR SEMAGLUTIDE: formulary differences are clinically meaningful given $900–1,200+/month list prices; CHOOSE TIRZEPATIDE (Zepbound/Mounjaro) WHEN: MAXIMUM WEIGHT LOSS IS THE PRIMARY GOAL: the −20.9% vs −14.9% differential translates to clinically meaningful outcome differences in obesity-related comorbidities; patients requiring ≥20% weight loss for remission of comorbidities (sleep apnea, PCOS, knee OA, NASH/MASH, T2DM remission) are better served by tirzepatide; INADEQUATE RESPONSE TO SEMAGLUTIDE: patients who plateau on maximal semaglutide dose should be considered for tirzepatide; up to 30% of patients on semaglutide are classified as "sub-responders" (<5% weight loss) — some may respond better to dual agonism; T2DM WITH OBESITY WHERE METABOLIC EFFICACY PRIORITY: SURPASS-2 head-to-head showed greater HbA1c reduction AND more than double the weight loss vs semaglutide 1mg; for T2DM patients who are obese, tirzepatide achieves both goals simultaneously at a level semaglutide cannot match; GLP-1 INTOLERANCE DUE TO NAUSEA: some patients who experienced severe nausea on semaglutide tolerate tirzepatide better (different receptor profile, slightly different GI kinetics); DOSE TITRATION: tirzepatide's 6-step titration (2.5mg starting dose is below any clinical effect → pure tolerance building) may result in a smoother tolerability experience than semaglutide's 4-step titration; BOTH DRUGS — KEY MONITORING: glucose in T2DM; pancreatitis symptoms (abdominal pain, nausea, vomiting); gallbladder disease (both increase gallstone risk proportional to weight loss rate); thyroid C-cell tumors (black box warning for both — based on rodent data; not observed in human epidemiology but contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2); lean mass preservation (both cause some muscle loss — resistance training is essential during treatment).